| Microorganism |
MIC50
(μg/ml) |
MIC90
(μg/ml) |
Range
(μg/ml) |
Antimicrobial |
Reference |
| Staphylococcus aureus (glycopeptide-intermediate-susceptible) |
- |
- |
2 － 8 |
Vancomycin (Vancocyn, Lyphocin)  |
1261 |
| Staphylococcus aureus (GN/sa-16) |
- |
- |
14 － ? |
Piperine |
1441 |
| Staphylococcus aureus (GO3) |
- |
- |
0.3 － ? |
RU79115 |
33 |
| Staphylococcus aureus (GO3) |
- |
- |
2.5 － ? |
Linezolid (PNU-100766, U-100766, Zyvox) |
33 |
| Staphylococcus aureus (GR56 + oxacillin-resistant) |
- |
- |
1.2 － ? |
Eperezolid (PNU-100592) |
33 |
| Staphylococcus aureus (GR56 + oxacillin-resistant) |
- |
- |
1.2 － ? |
Vancomycin (Vancocyn, Lyphocin) |
33 |
| Staphylococcus aureus (GR56 oxacillin-resistant) |
- |
- |
0.08 － ? |
RU79115 |
33 |
| Staphylococcus aureus (grl(A) + gyr(A) + flq(B)) |
- |
- |
8 － ? |
Moxifloxacin (BAY 12-8039, Avelox) |
461 |
| Staphylococcus aureus (grl(A) + gyr(A) + flq(B)) |
- |
- |
16 － ? |
Gatifloxacin (Tequin) |
461 |
| Staphylococcus aureus (grl(A) + gyr(A) + flq(B)) |
- |
- |
32 － ? |
Ethidium bromide (EtBr) |
461 |
| Staphylococcus aureus (grl(A) + gyr(A) + flq(B)) |
- |
- |
256 － ? |
Ciprofloxacin (Cipro, Ciproxin, Ciprobay) |
461 |
| Staphylococcus aureus (grl(A) + gyr(A) + flq(B)) |
- |
- |
2048 － ? |
Norfloxacin (Noroxin) |
461 |
| Staphylococcus aureus (grl(A) + gyr(A) + methicillin-resistant) |
- |
- |
0.5 － ? |
Moxifloxacin (BAY 12-8039, Avelox) |
461 |
| Staphylococcus aureus (grl(A) + gyr(A) + methicillin-resistant) |
- |
- |
1 － ? |
Gatifloxacin (Tequin) |
461 |
| Staphylococcus aureus (grl(A) + gyr(A) + methicillin-resistant) |
- |
- |
2 － ? |
Moxifloxacin (BAY 12-8039, Avelox) |
461 |
| Staphylococcus aureus (grl(A) + gyr(A) + methicillin-resistant) |
- |
- |
4 － ? |
Ethidium bromide (EtBr) |
461 |
| Staphylococcus aureus (grl(A) + gyr(A) + methicillin-resistant) |
- |
- |
4 － ? |
Ethidium bromide (EtBr) |
461 |
| Staphylococcus aureus (grl(A) + gyr(A) + methicillin-resistant) |
- |
- |
4 － ? |
Ethidium bromide (EtBr) |
461 |
| Staphylococcus aureus (grl(A) + gyr(A) + methicillin-resistant) |
- |
- |
4 － ? |
Gatifloxacin (Tequin) |
461 |
| Staphylococcus aureus (grl(A) + gyr(A) + methicillin-resistant) |
- |
- |
4 － ? |
Moxifloxacin (BAY 12-8039, Avelox) |
461 |
| Staphylococcus aureus (grl(A) + gyr(A) + methicillin-resistant) |
- |
- |
8 － ? |
Gatifloxacin (Tequin) |
461 |
| Staphylococcus aureus (grl(A) + gyr(A) + methicillin-resistant) |
- |
- |
16 － ? |
Ciprofloxacin (Cipro, Ciproxin, Ciprobay) |
461 |
| Staphylococcus aureus (grl(A) + gyr(A) + methicillin-resistant) |
- |
- |
32 － ? |
Ciprofloxacin (Cipro, Ciproxin, Ciprobay) |
461 |
| Staphylococcus aureus (grl(A) + gyr(A) + methicillin-resistant) |
- |
- |
64 － ? |
Ciprofloxacin (Cipro, Ciproxin, Ciprobay) |
461 |
| Staphylococcus aureus (grl(A) + gyr(A) + methicillin-resistant) |
- |
- |
64 － ? |
Norfloxacin (Noroxin) |
461 |
| Staphylococcus aureus (grl(A) + gyr(A) + methicillin-resistant) |
- |
- |
128 － ? |
Norfloxacin (Noroxin) |
461 |
| Staphylococcus aureus (grl(A) + gyr(A) + methicillin-resistant) |
- |
- |
256 － ? |
Norfloxacin (Noroxin) |
461 |
| Staphylococcus aureus (grl(A) + gyr(A)) |
- |
- |
2 － ? |
Moxifloxacin (BAY 12-8039, Avelox) |
461 |